output of the Bsep and Mrp2 substrates, taurocholate, and dinitrophenyl-S-glutathione, respectively. The changes in Bsep/Mrp2 and F-actin localization induced by tBuOOH, as assessed by (immuno)fluorescence staining followed by analysis of confocal images, were prevented total or partially by the MAPK inhibitors. We concluded that MAPKs of the ERK1/2, JNK1/2, and p38
Introduction
Oxidative stress (OS) is a common feature in most hepatopathies, including drug and environmental toxininduced hepatotoxicity, hepatic ischemia-reperfusion injury, viral and autoimmune hepatitis, alcoholic and nonalcoholic steatohepatitis, and pathologies leading to hepatic accumulation of either heavy metals, such as iron (hemochromatosis) and copper (Wilson's disease), or bile acids (obstructive or functional cholestasis) (Copple et al. 2010; Jaeschke et al. 2002) .
In recent years, evidence has accumulated that, in cholestatic hepatopathies, a vicious circle occurs, since OS is cholestatic in nature, thus aggravating the initial secretory failure . Indeed, our group demonstrated in isolated rat hepatocyte couplets (IRHCs) that OS induces rapid endocytic internalization of the bile salt export pump (Bsep, AKA: Abcc11) (Perez et al. 2006b ), the main canalicular bile salt transporter. A similar Abstract In previous studies, we showed that the prooxidant model agent tert-butyl hydroperoxide (tBuOOH) induces alterations in hepatocanalicular secretory function by activating Ca 2+ -dependent protein kinase C isoforms (cPKC), via F-actin disorganization followed by endocytic internalization of canalicular transporters relevant to bile formation (Mrp2, Bsep). Since mitogen-activated protein kinases (MAPKs) may be downstream effectors of cPKC, we investigated here the involvement of the MAPKs of the ERK1/2, JNK1/2, and p38
MAPK types in these deleterious effects. tBuOOH (100 µM, 15 min) increased the proportion of the active, phosphorylated forms of ERK1/2, JNK1/2, and p38 MAPK , and panspecific PKC inhibition with bisindolylmaleimide-1 (100 nM) or selective cPKC inhibition with Gö6976 (1 μM) prevented the latter two events. In isolated rat hepatocyte couplets, tBuOOH (100 µM, 15 min) decreased the canalicular vacuolar accumulation of the fluorescent Bsep and Mrp2 substrates, cholylglycylamido fluorescein, and glutathione-methylfluorescein, respectively, and selective inhibitors of ERK1/2 (PD098059), JNK1/2 (SP600125), and p38 MAPK (SB203580) partially prevented these alterations. In in situ perfused rat livers, these three MAPK inhibitors prevented tBuOOH (75 µM)-induced impairment of bile flow and the decrease in the biliary Electronic supplementary material The online version of this article (doi:10.1007/s00204-016-1898-1) contains supplementary material, which is available to authorized users.
phenomenon was described for multidrug resistance-associated protein 2 (Mrp2, Abcc2) (Schmitt et al. 2000; Sekine et al. 2011; Ji et al. 2004) , another canalicular transporter highly relevant to bile formation by mediating the biliary excretion of glutathione, the other main driving force of bile formation together with bile salts.
We also showed a close link between internalization of canalicular transporters and actin cytoskeleton disarrangement, an alteration that has been shown to onset canalicular transporter endocytosis (Rost et al. 1999) . Under OS conditions, actin redistributes from the pericanalicular zone to the rest of cell body, through a mechanism involving calcium-dependent isoenzymes of protein kinase C (cPKC) (Perez et al. 2006a, b) ; this may occur via both increase of intracellular calcium levels (Stone et al. 1994 ) and direct activation of cPKC via oxidative modifications (CosentinoGomes et al. 2012) .
The exact mechanisms that explain the deleterious effect of cPKC on actin integrity and, by extension, on the hepatocanalicular function have not been yet elucidated. PKC may activate downstream signaling pathways able to intermediate cytoskeletal perturbations, and the signaling pathways mediated by mitogen-activated protein kinases (MAPKs) are likely candidates; our previous finding that PKA activation counteracts OS-induced hepatocanalicular dysfunction (Perez et al. 2006a, b ) also points to MAPKs, since PKA exerts inhibitory cross talk on MAPK activation (Cook and McCormick 1993) .
MAPKs are evolutionarily conserved serine/threoninespecific protein kinases involving three major subfamilies, namely extracellular signal-regulated kinases (ERK1/2, ERK3/4, ERK5, ERK7/8), Jun N-terminal kinases (JNK1/2/3), and p38 MAPK (p38 MAPK α/β/γ/δ) (Kyriakis and Avruch 2012). They respond to a wide range of hormones and extracellular stressors, including OS (Kyriakis and Avruch 2012) . After recognition of these effectors by surface receptors, MAPKs are activated by three-tiered, sequential phosphorylations mediated by small GTP-binding proteins (e.g., Ras, Rap) and two further protein kinases (MAPKKK and MAPKK), which act as dual-specificity enzymes that activate a selective MAPK type. Non-canonical activation of MAPKs also exists, via either MAPK autophosphorylation or direct MAPK phosphorylation by alternative protein kinases, such as Src or ZAP70 (Pimienta and Pascual 2007) .
Activation of MAPKs is triggered by OS in most organs, including liver (Kyriakis and Avruch 2012) . Radical oxygen species (ROS) from different sources induced ERK1/2, JNK1/2, and p38
MAPK activation in murine hepatocytes (Rosseland et al. 2005; de la Conde et al. 2006; Abdelmegeed et al. 2004) , as well as in hepatoma cell lines (Nguyen et al. 2013; Liu et al. 2011) . Similarly, PKC can activate MAPKs in hepatocytes (Romanelli and van de Werve 1997) , an effect that is thought to be mediated by Ras (Malumbres and Pellicer 1998) . More relevant to our case, MAPKs are activated by PKC under OS conditions in hepatocytes (Lee et al. 2008; Gao et al. 2004) .
This prompts us to hypothesize that MAPKs are involved in OS-induced, cPKC-mediated impairment of the hepatocanalicular function and cholestasis. To confirm this contention, we analyzed the role for MAPKs in cholestasis induced by the pro-oxidizing compound tBuOOH, in two in vitro models for the study of biliary secretion, namely IRHCs and in situ perfused rat livers (PRLs). tBuOOH is a short-chain analog of lipid peroxides widely used to mimic the deleterious effect that lipid peroxides produced during the OS-induced lipid oxidation cascade; like endogenous lipid peroxides, tBuOOH generates, after metabolic activation, peroxyl and alkoxyl radicals, with the former being most likely involved in cholestatic effects (Ahmed-Choudhury et al. 1998 ).
Materials and methods

Materials
Collagenase type A (from Clostridium histolyticum), bovine serum albumin (fraction V), tBuOOH, dimethyl sulfoxide (DMSO), 1-chloro-2,4-dinitrobenzene (CDNB), sodium taurocholate, trypan blue, leibovitz-15 (L-15) culture medium, ethylene glycol tetraacetic acid, tetramethylethylenediamine, urethane, phenylmethylsulfonyl fluoride (PMSF), reduced nicotinamide adenine dinucleotide phosphate, and Triton X-100 were purchased from Sigma Chemical Co. (St. Louis, MO, USA). 5-Chloromethylfluorescein diacetate (CMFDA) and Alexa Fluor 568 phalloidin were purchased from Molecular Probes (Eugene, OR, USA, EE.UU.). Gö6976, bisindolylmaleimide-1 (BIM-1), PD980589, SB203580, and SP600125 were purchased from Calbiochem (San Diego, CA, USA, EE.UU. All the other reagents were of the highest purity commercially available.
Animals
Adult male Wistar rats weighing 300-350 g (8 to 10 weeks old) were used throughout. Animals were maintained on a standard diet and water ad libitum, and housed in a temperature-and humidity-controlled room under a constant 12-h light/12-h dark cycle. Treatments were carried out under urethane anesthesia (1 g/kg, i.p.). All animals received humane care according to the criteria outlined in the "Guide for the Care and Use of Laboratory Animals," by the National Academy of Sciences and published by the National Institutes of Health (NIH publication 25-28, revised 1996) .
Western blot analysis of MAPK phosphorylation
Activation of p38 MAPK , ERK1/2, and JNK1/2 was assessed by evaluating by Western blotting the phosphorylation status of these MAPKs in lysates of primary-cultured rat hepatocytes. Briefly, isolated rat hepatocytes were obtained by collagenase perfusion, as described elsewhere (Berry and Friend 1969) , and cultured in 3-cm Petri dishes with DMEM supplemented with 10% FCS and antibiotics (penicillin, streptomycin), at the density of 2 × 10 6 cells/ ml. After 24 h of culture, cells were exposed to tBuOOH (100 µM) for 5, 15, and 30 min, or for 15 min in cells pretreated for 15 min with either the cPKC inhibitor Gö6976 (1 µM) (Perez et al. 2006a, b) or the panspecific PKC inhibitor BIM-1 (100 nM) (Zegers and Hoekstra 1997) , washed with cold phosphate-buffered saline, and finally resuspended in cell lysis buffer and protease inhibitor cocktail. Aliquots containing equivalent total protein content, as determined by the Lowry procedure with BSA as the standard (Lowry et al. 1951) , were subjected to sodium dodecyl sulfate/12% polyacrylamide gel electrophoresis, electrotransferred to Immobilon-P membranes, and probed overnight with rabbit antiphosphorylated p38 MAPK (1:300), rabbit antiphosphorylated ERK1/2 (1:1000), or mouse antiphosphorylated JNK1/2 (1:2000) antibodies. Stripped membranes were reprobed with rabbit antitotal p38 MAPK (1:1000), rabbit antitotal ERK1/2 (1:1000), and mouse antitotal JNK1/2 (1:1000) antibodies. After exposure to donkey antirabbit IgG secondary antibody or a goat antimouse IgG (1:5000, 1 h, Thermo Fisher Scientific, Waltham, MA, USA), protein bands were visualized using a chemiluminescence reagent (ECL™-GE Healthcare, USA), and captured with Hyperfilm ECL™ (GE Healthcare, Amersham, USA); the autoradiography film was manually scanned, and the densitometry data were obtained by using the ImageJ 1.34 m software (NIH, USA).
Studies in isolated rat hepatocyte couplets
Couplets isolation, enrichment, culture, and treatments
IRHCs were obtained according to the two-step collagenase perfusion procedure, followed by centrifugal elutriation (Wilton et al. 1991) . The resulting preparation, containing 70 ± 4% of couplets of high viability (>95%), was plated onto 24-well plastic plates, at a density of 5 × 10 4 units/ ml, and incubated at 37 °C for 4.5 h, for attachment and repolarization. Then, IRHCs were incubated with tBuOOH (100 μM, 15 min) or DMSO (vehicle; 0.2-0.5% v/v) in controls; at the 100 μM concentration, tBuOOH had been shown to impair by ~50% Bsep-mediated canalicular transport function in IRHCs (Ahmed-Choudhury et al. 1998), whereas 0.5% v/v DMSO was without effect on this parameter (Perez et al. 2006a) , and on blebbing/actin organization (Perez et al. 2006b ).
To assess the involvement of MAPK in the deleterious effect induced by tBuOOH, the MAPK inhibitors SB203580 (1 µM, p38 MAPK inhibitor), PD098059 (50 µM, MEK inhibitor), or SP600125 (1 µM, JNK inhibitor) was added to the culture medium for 15 min prior to exposure to tBuOOH, and kept further during the exposure to this pro-oxidant compound.
Assessment of biliary secretory function in IRHCs
Bsep function was evaluated by assessing the proportion of couplets (>200/preparation) displaying canalicular vacuolar accumulation (CVa) of the fluorescent bile salt analog CGamF, a fluorescent Bsep substrate (Maglova et al. 1995) , as described previously . Similarly, Mrp2 function was evaluated through its ability to secrete glutathione-S-methylfluorescein (GS-MF), the fluorescent glutathione-conjugated metabolite of CMFDA; this latter compound diffuses passively, and is intracellularly metabolized by esterases and glutathione-S-transferases to render GS-MF (Roelofsen et al. 1998 ).
Assessment of bleb formation
Blebbing, a preliminary marker of F-actin cytoskeleton disruption (Gores et al. 1990) , was quantified by using light microscopy, assessing the proportion of IRHCs exhibiting at least one bleb in either of the two cells, referred to the total number of IRHCs analyzed (>50) (Stone et al. 1994) .
Bsep, Mrp2, and F-actin localization
Bsep and Mrp2 immunostaining was carried out as described elsewhere (Crocenzi et al. 2008) . Briefly, paraformaldehyde-fixed IRHCs were incubated with antibodies to Bsep or Mrp2 (1:100) for 2 h, followed by incubation with Cy2-labeled antirabbit (or antimouse) IgG goat antibody (1:200), or with Alexa Fluor 568 phalloidin for F-actin, for a further 40-min period. Densitometric analysis of confocal images taken with a Zeiss Pascal LSM 5 (Carl Zeiss, Walldorf, Germany) was carried out to assess the localization of both Bsep/Mrp2 and F-actin. The canalicular vacuole was delimited by superposing each fluorescence image with its respective differential interface contrast (DIC) image (Boaglio et al. 2012) . Intensity of Bsep/Mrp2-associated fluorescence was quantified along an 8-µm line perpendicular to the canalicular vacuole (from −4 to +4 µm of the canalicular center), as described elsewhere (Boaglio et al. 2012) . The proportion of F-actin confined to its normal pericanalicular localization was also quantified. For this purpose, this pericanalicular region was delimited by determining the area surrounding the bile canaliculi of control IRHCs where the pixels had a F-actin-associated fluorescence intensity at least twice of that of the background. This area was no wider than 1 µm, a value close to that reported elsewhere (Serriere et al. 2008 ).
Studies in PRLs
Rat liver perfusion
Livers from bile duct-cannulated rats (Intramedic PE-10 tubing, Clay Adams) were perfused in situ in a non-recirculating system, as described elsewhere (Crocenzi et al. 2008) . Experiments exhibiting lactate dehydrogenase activities >20 U/l in the perfusate outflow were considered unviable.
After a 20-min stabilization period, SB203580 (250 nM), PD98059 (5 µM), SP600125 (1 µM), or their solvent, DMSO, was added, and allowed to act throughout the whole perfusion period. After 15 min of pretreatment with each MAPK inhibitor, tBuOOH (or DMSO) was added to the reservoir at a 75 µM concentration, and allowed to act for a further 10-min period. Finally, tBuOOH perfusion was stopped, and the livers were perfused only with each of the MAPK inhibitors. Bile was collected at 10-min intervals throughout the experiment.
Bile flow was estimated gravimetrically. We also calculated the outputs of the Bsep substrate taurocholate (added to the reservoir at a 2.5 μM concentration) and of the Mrp2 substrate 2,4-dinitrophenyl-S-glutathione (DNP-SG), produced intracellularly by glutathione conjugation of CDNB (added to the reservoir at a 0.5 μM concentration). Taurocholate was assessed in bile by the 3α-hydroxysteroid dehydrogenase procedure (Talalay 1960) . Biliary DNP-SG was determined by HPLC, as described elsewhere (Mottino et al. 2001) . At the end of the experiment, livers were removed, and sections were rapidly frozen in dry-icechilled isopentane, and stored at −70 °C until use.
Immunohistochemical detection of Bsep, Mrp2, and F-actin
Confocal microscopy was used to visualize Bsep/Mrp2 endocytic internalization and F-actin disorganization, as previously described . Briefly, liver slices (5 µm) were prepared with a Zeiss Microm HM500 microtome cryostat, and fixed for 10 min with 3% paraformaldehyde, in PBS. For Bsep and Mrp2 labeling, tissue sections were incubated overnight with the specific antibody to Bsep or Mrp2 (1:100). Sections were then incubated with Cy2-conjugated donkey antirabbit IgG (1:100) and Alexa Fluor 568 phalloidin (for F-actin staining), for 1 h. Then, slices were mounted, and analyzed by confocal microscopy.
Statistical analysis
Statistical analysis was performed by using GraphPad Prism software (GraphPad, San Diego, CA, USA). Results were expressed as mean ± SEM. When requirements for parametric analysis were met, a Student's unpaired t test was used for comparison between two groups; comparisons between two groups that did not meet this criterion were made using the Mann-Whitney's rank-sum test. Multiple groups were compared by one-way analysis of variance (ANOVA) or, when normality test failed, by nonparametric Kruskal-Wallis test (one-way ANOVA by ranks). If ANOVA reached any statistical significance among groups, pairwise multiple comparisons were made by using Tukey's or Dunn's tests, respectively. The variances of the densitometric profiles of Bsep and Mrp2 localization were compared with the Mann-Whitney U test. p values lower than 0.05 were judged to be significant.
Results
MAPK activation by tBuOOH and dependency on cPKC
The time course of p38 MAPK , ERK1/2, and JNK1/2 activation after exposure of cultured rat hepatocytes to tBuOOH, as determined by the increase in the phosphorylated, active forms of these enzymes, is shown in Fig. 1a . Western blots of phospho-(p)-ERK1/2, p-JNK1/2, and, p-p38 MAPK showed that tBuOOH increased the amount of the each p-MAPK in a time-dependent manner, with increments becoming apparent by 5 min after tBuOOH exposure.
As shown in Fig. 1b , pretreatment with the cPKC inhibitor Gö6976 selectively prevented the increase in p-p38 MAPK and p-JNK1/2, but no that of p-ERK1/2, indicating that activation of p38 MAPK and JNK1/2 depends upon cPKC, whereas activation of ERK1/2 depends on an alternative, unidentified redox-sensitive signaling pathway. To control for putative Gö6976 inhibitory unspecificity toward other redox-sensitive kinases, the structurally and mechanistically unrelated PKC inhibitor BIM-1 was assayed as well, and it inhibited p38 MAPK and JNK1/2 to the same extent as Gö6976.
MAPKs play a role in tBuOOH-induced impairment of function and localization of Bsep and Mrp2 in IRHCs
The percentage of couplets able to accumulate in their canalicular vacuoles the fluorescent Bsep and Mrp2 substrates CGamF and GS-MF, respectively, is shown in Fig. 2 . Control couplets exposed only to DMSO (tBuOOH vehicle) showed a 65-70% CVa of each fluorescent substrate. While tBuOOH caused a decrease in the percentage of couplets accumulating apically both fluorescent substrates, pretreatment with the JNK1/2 inhibitor SP600125 (1 µM), the ERK inhibitor PD098059 (5 and 50 µM), and the p38 MAPK inhibitor SB203580 (1 µM) partially prevented these effects. None of these inhibitors modified the apical accumulation of both substrates per se (Supplementary Table 1) .
Confocal immunolocalization studies in control IRHCs showed that both Bsep and Mrp2 were mainly confined to the canalicular membrane, while tBuOOH induced relocalization of Bsep and Mrp2 into intracellular vesicles, indicating endocytosis (Fig. 3, upper graphs of panels a, b, respectively) . All the MAPK inhibitors partially prevented this effect.
These findings were confirmed by densitometric analysis. Densitometric curves showed a flatter Bsep and Mrp2 fluorescence profile in tBuOOH-treated IRHCs, as compared to controls (Fig. 3 , lower graphs of panels a, b, respectively). In IRHCs pretreated with either of the MAPK inhibitors, densitometric curves were statistically less flat than that of tBuOOH alone (p < 0.05).
MAPKs are involved in tBuOOH-induced blebbing and F-actin redistribution
Bleb formation was assessed as a preliminary marker of cytoskeleton disruption (Gores et al. 1990) , by phasecontrast microscopy. As shown in Fig. 4a , control cells exposed only to the tBuOOH solvent, DMSO, showed a low background blebbing (<18%), which consisted usually of a single, small bleb per cell (type 1 blebbing). In contrast, tBuOOH induced extensive bleb formation, often visualized as multiple membrane protrusions distributed all over the cell surface (type 2 blebbing). Individual pretreatments with each of the MAPK inhibitors fully prevented this effect. None of these inhibitors induced blebbing per se (Supplementary Table 1) .
F-actin distribution was also analyzed by confocal microscopy under the same conditions (Fig. 4b) . In control IRHCs, F-actin displayed a predominant pericanalicular localization, forming a dense belt beneath the canalicular membrane. In tBuOOH-treated IRHCs, bleb formation was accompanied by extensive redistribution of F-actin from the pericanalicular area to the sinusoidal plasma membrane region. Redistribution of F-actin was extensively prevented by pretreatment of IRHCs with either of the MAPK inhibitors.
tBuOOH induces cholestasis by a MAPK-mediated mechanism in PRLs
Livers were perfused with tBuOOH (75 µM) for 10 min, in the presence or absence of the JNK1/2 inhibitor SP600125, the ERK inhibitor PD098059, and the p38 MAPK inhibitor SB203580 (Fig. 5) ; 75 µM tBuOOH closely reproduced the extent of bile salt secretory failure reached in IRHCs exposed to 100 µM tBuOOH.
Initial exposure of PRLs to the MAPK inhibitors did not significantly influence bile flow. On the other hand, bile flow dropped sharply after the onset of tBuOOH perfusion, with a nadir to ~60% of control values at 20 min, and a trend toward recovery of bile flow afterward; this is likely due to both the efficient reductive detoxification of tBuOOH (Rush and Alberts 1986 ) and the further spontaneous recovery of actin organization and canalicular transport function, which was shown to occur quickly in the IRHC model (Perez et al. 2006a, b) . All the MAPK inhibitors significantly prevented this bile flow decrease, with bile flow profiles approaching that of control (Fig. 5a) .
Since Bsep and Mrp2 are key determinants of bile flow, we assessed the capability of the MAPK inhibitors to prevent their functional impairment induced by tBuOOH. The pro-oxidant induced a ~85% and a ~60% of decrease in the excretion of the Bsep and Mrp2 substrates taurocholate and DNP-SG, respectively, but this effect was prevented when the MAPK inhibitors were present (Fig. 5b, c, respectively) .
MAPKs are involved in the changes of Bsep, Mrp2, and F-actin localizations induced by tBuOOH
Tissue sections obtained from PRLs after 20 min of the onset of tBuOOH exposure were subjected to co-staining and densitometric analysis showing the dependency on cPKC activity of the activation of MAPKs by tBuOOH, as assessed by exposing primary-cultured hepatocytes to the PKC inhibitors Gö6976 (Gö, 1 µM) or BIM-1 (100 nM) for 15 min, and then exposed to tBuOOH (100 µM) for a further 15-min period. Control group received only Gö/BIM-1 and tBuOOH vehicle (DMSO). The results are mean ± SEM, from four independent experiments. a Significantly different from control (p < 0.05); b significantly different from tBuOOHtreated hepatocytes (p < 0.05) of Bsep and F-actin, or Mrp2 and F-actin. In control livers, transporter-associated fluorescence was confined to the canalicular space (Fig. 6) . In tBuOOH-treated livers, the carriers relocalized from the canalicular space to the pericanalicular, as indicated by the increased fluorescence at a greater distance from the bile canaliculus. Exposure to ERK1/2, JNK1/2, and p38 MAPK inhibitors significantly prevented these alterations.
Discussion
In previous works, we demonstrated that tBuOOH induces alterations in the secretory function in IRHCs via activation of cPKC, through a mechanism that involves disorganization of the F-actin cytoskeleton, and subsequent endocytic internalization of canalicular transporters responsible for bile formation, Bsep and Mrp2 (Perez et al. 2006a, b) . In this work, we extended this finding by showing that MAPKs of the ERK1/2, JNK1/2, and p38 MAPK types are all involved in OS-induced cholestasis as well, and that, for JNK1/2 and p38 MAPK , cPKC is an upstream activator. On the other hand, ERK1/2 activation by tBuOOH does not seem to be mediated by cPKC; this is in line with the finding that ERK1/2 was activated by hydrogen peroxide via Ca 2+ -and PKC-independent mechanisms in cardiomyocytes, involving instead the Src family of tyrosine kinases Ras and Raf-1 (Aikawa et al. 1997 ). Another possible redox-sensitive kinase that can be involved upstream of ERK1/2 is apoptosis-stimulating kinase 1 (ASK-1), a serine/threonine kinase of the MKKK family; ASK1 can be activated by ROS-mediated oxidation of its physiological inhibitor, thioredoxin, with whom ASK1 forms an inactive complex (Saitoh et al. 1998) . Whether these MAPKs directly phosphorylate cytoskeletal proteins to induce F-actin relocalization and further impairment in canalicular transporter localization is unknown. There is accumulating evidence in other epithelial cell types that this may be the case. For example, ethanol induced disruption of F-actin and the subsequent opening of intercellular tight junctions through oxidative mechanisms in Caco-2 cells, a polarized in vitro model of intestinal epithelium (Elamin et al. 2014 ) and, as in our case, the MAPKs of the p38 MAPK , ERK1/2, and JNK1/2 types need to be all active for this deleterious effect to occur. The event also involved the phosphorylation of myosin light chain kinase (MLCK), which favors the formation of cross-links with F-actin by phosphorylating myosin light chain (MLC); once phosphorylated, MLC generates a myosin-F-actin contractile force, with the resulting increase in cytoplasm tension and bleb formation (Elamin et al. 2014 ). It has also been shown in livers subjected to ischemia/ reperfusion that p38 MAPK induces activation of heat-shock protein 27 (HSP27) (Keller et al. 2005) , a protein that promotes the formation of cross-links between F-actin and myosin by inhibiting the phosphorylation of caldesmon, a physiological inhibitor of the myosin-F-actin interaction (Somara and Bitar 2006) . In addition, ERK1/2 may directly phosphorylate caldesmon in vivo, thus reinforcing this effect (Hedges et al. 2000) . A similar phenomenon was reported in the human liver cell line HL7702 exposed to the phosphatase 2A inhibitor microcystin-LR, a toxin that promotes cytoskeletal reorganization by inducing p38 MAPK -and JNK1/2-mediated phosphorylation of HSP27 Fig. 3 Protective effect of MAPK inhibitors on the changes in Bsep and Mrp2 localization induced by tBuOOH in IRHCs. Confocal images showing localization of a Bsep and b Mrp2, after exposure to tBuOOH (100 µM) for 15 min, in the absence or presence of the ERK1/2 inhibitor PD098059 (PD, 50 µM), the JNK1/2 inhibitor SP600125 (SP, 1 µM), or the p38 MAPK inhibitor SB203580 (SB, 1 µM), administered 15 min before addition of tBuOOH; insets are the corresponding DIC images. After these treatments, IRHCs were fixed and immunostained for Bsep or Mrp2, as described in "Materials and methods" section. Location of the transporters was evaluated by image analysis of the photographs obtained, by assessing the distribution pattern of fluorescence intensity along an axis perpendicular to the canalicular vacuole (4 µm to each side of the canalicular center), using the image analysis program Image J 1.34 m software (Improvision, Coventry, NIH). Statistical analysis of the fluorescence profiles showed a significant change in tBuOOH-treated IRHCs (p < 0.05; number of canalicular vacuoles analyzed >10, from three independent experiments per group), with a decrease in the fluorescence intensity in the canalicular area, together with an increased fluorescence at a greater distance from the canalicular vacuole, which was counteracted by the MAPK inhibitors (Sun et al. 2011) . In a pro-apoptotic context, MLC phosphorylation and the resulting bleb formation may also be mediated by the serine/threonine protein kinase ROCK I, which is activated by caspase-3-dependent cleavage (Sebbagh et al. 2001) . Although apoptosis is a well-recognized event in hepatocytes exposed to high tBuOOH concentrations Sarkar and Sil 2010; Tripathi et al. 2009 ), at the low concentration used here (100 µM), tBuOOH showed no sign of caspase-3 activation, as well as of other hallmarks of apoptosis, such as appearance of nuclei with subdiploid DNA content and cytochrome-c release (Gómez-Lechón et al. 2002) . However, bleb formation may precede these apoptotic changes (Barros et al. 2003) , and therefore we cannot rule that blebbing and the consequent canalicular dysfunction occurring at low tBuOOH levels represent a very early event of an ongoing apoptotic process. Interestingly, Deschesnes et al. (2001) showed that blebbing in c-Myc-dependent apoptosis of rat-1 cells was independent of caspase activity, but dependent of p38 MAPK -sensitive changes in microfilament dynamics, a phenomenon likely mediated by HSP27 phosphorylation. The functional status of canalicular transporters during the apoptotic process and its relationship with the cytoskeletal perturbations induced by OS is a pending, intriguing issue that deserves further investigation.
MAPKs could also change canalicular transporter location by activating mechanisms leading to radixin phosphorylation. Expression of constructs that mimic a permanently phosphorylated (active) form of radixin in the polarized, hybrid hepatoblastoma/human fibroblast cell line WIF-B led to redistribution of radixin from the canalicular to the basolateral membrane, probably as a consequence of a more promiscuous interaction of its active, phosphorylated form with both apical and basolateral pools of F-actin; this would lead to relocation of the canalicular transporters (Suda et al. 2011) . Furthermore, activation of radixin by p38 MAPK -dependent phosphorylation of Thr-564 has been shown in several cell lines, through a signaling mechanism which, like in our case, involves PKC activation (Zhang et al. 2014; Bogatcheva et al. 2011) . Contrarily to this view, an impaired rather than an enhanced phosphorylation of radixin has been proposed to account for Mrp2 endocytosis under OS conditions in IRHCs; this would involve protein phosphatase PP-1-dependent dephosphorylation of radixin via PKC-induced PP-1 activation, leading to instability of Mrp2 in the plasma membrane by loss of cross-linking with actin filaments (Sekine et al. 2011) . This latter view is somewhat difficult to reconcile with our finding of significant ERK1/2 activation, since PP-1 was shown to prevent this activation presumably by dephosphorylation of the upstream enzymes, MEK and Raf (Schaeffer and Weber 1999) .
MAPK dependence of tBuOOH-induced cholestasis is somewhat paradoxical with previous works showing that ERK1/2 and p38 MAPK are both involved in choleretic phenomena, such as those induced by tauroursodeoxycholate Fig. 4 Effect of MAPK inhibitors on tBuOOH-induced blebbing and disruption of F-actin cytoskeleton in IRHCs. a Bleb formation and b changes in F-actin distribution after exposure to tBuOOH (100 µM) for 15 min, in the presence or absence of the ERK1/2 inhibitor PD098059 (PD, 50 µM), the JNK1/2 inhibitor SP600125 (SP, 1 µM), or the p38 MAPK inhibitor SB203580 (SB, 1 µM), administered 15 min before tBuOOH addition. Bleb formation was assessed by phase-contrast microscopy. F-actin distribution was assessed by staining with fluorescently labeled phalloidin, followed by confocal microscopy, and further image analysis for quantification of the proportion of fluorescence intensity localized in the pericanalicular zone. The number of IRHCs analyzed per group was >30, obtained from a minimum of three independent preparations. Values are mean ± SEM. (Kurz et al. 2001; Schliess et al. 1997; Kubitz et al. 2004 ) and cAMP (Schonhoff et al. 2010) . For example, TUDC stimulates excretion of the choleretic bile salt taurocholate via an integrin-dependent signaling pathway involving both Ras/Raf/MEK/ERK1/2 and Src/p38 MAPK (Häussinger et al. 2003) , as a result of stimulation of the Bsep trafficking from Golgi to the canalicular membrane (Kubitz et al. 2004) . The reason for the paradoxical mediation of MAPKs of opposite (choleretic and cholestatic) effects on bile flow under normal and oxidative conditions, respectively, is unclear at present, but could be due to the following reasons:
1. MAPKs activation is highly compartmentalized, requiring localization at specific sites of scaffold proteins to allow regional recruitment of the multiple components of the MAPK cascade (Canal et al. 2011) . In quiescent hepatocytes, Raf-1 and MEK are located only in early endosomes, which are the first endosomal compartment to receive endocytosed transporters (Pol et al. 1998) . Therefore, the rapid cholestatic effects induced by tBuOOH in our acute exposure model may involve events limited to "early" compartment, such as endocytosis of transporters to subapical endosomes. Contrarily, the choleretic effects involving trafficking of transporters from Golgi/post-Golgi compartments to the canalicular membrane would be a later event, occurring when trafficking of scaffold proteins to deeper levels is stimulated by the choleretic stimulus (Philips 2004 by us for the cholestatic agent estradiol 17ß-glucuronide, which also required cPKC-dependent MAPK activation to induce cholestasis (Boaglio et al. 2012 ).
3. Choleretic and cholestatic compounds (in this case, tBuOOH) might activate MAPK isoforms with opposite effects on bile flow. For example, α-and β-p38 MAPK isoforms mediate choleretic and cholestatic effects of bile salts, respectively (Anwer 2012; Schonhoff et al. 2010) . 4. As shown here, the three MAPK types need to be activated simultaneously by tBuOOH to exert its cholestatic effects, and this may not be the case for choleretic compounds; for example, the choleretic bile salt TUDC activates p38 MAPK and ERK1/2, but not JNK1/2 (Kurz et al. 2001) .
Although more studies are needed to determine with certainty the molecular mechanisms by which the MAPKs induced cholestasis when activated in an oxidative context, our results show that the interaction of MAPKs with actin cytoskeleton is critical for the endocytic internalization of canalicular carriers relevant for bile formation, thus explaining the cholestatic phenomenon. Drugs that selectively inhibit MAPKs are used in preclinical and clinical studies with reasonable success (Chapman and Miner 2011) . Given the existence of clinical cholestatic liver diseases in humans associated with high levels of OS, our results may help to envisage complementary therapeutic strategies to treat these diseases by using therapeutic tools that are already within our reach. Representative confocal images illustrating the endocytic internalization of Bsep and Mrp2, together with the disruption of F-actin cytoskeleton induced by tBuOOH (75 µM, 10 min), and its prevention by the ERK1/2 inhibitor PD098059 (PD, 5 µM), the JNK1/2 inhibitor SP600125 (SP, 1 µM), or the p38 MAPK inhibitor SB203580 (SB, 250 nM), administered 15 min before tBuOOH (or DMSO in controls). Images were taken 20 min after the onset of perfusion with tBuOOH. a Co-staining of Bsep (green) and F-actin (red); b co-staining of Mrp2 (green) and F-actin (red). In control livers, both Bsep and Mrp2 were mainly confined to the canalicular space, whereas in livers treated with tBuOOH, relocalization of intracellular fluorescence associated with both Bsep and Mrp2 from the canalicular space to the pericanalicular area was apparent, thus indicating endocytic internalization of the transporters. The MAPK inhibitors prevented this phenomenon, as illustrated by a control-like pattern of the Bsep and Mrp2 distribution in livers preperfused with the MAPK inhibitors. Regarding cytoskeleton integrity, pericanalicular localization of F-actin was evident in control livers, while a severe disarrangement of F-actin was observed in livers perfused with tBuOOH. MAPK inhibitors partially prevented tBuOOH-induced disturbances on F-actin cytoskeleton, thus explaining their protective effects on canalicular transporter localization and function (color figure online) 
